Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Forward Pharma (FWP) Halted LUDP; Shares Down 19%
January 29, 2018 11:20 AM ESTForward Pharma (NASDAQ: FWP) halted LUDP; Shares down 19% as trading resumes
... MoreBiogen (BIIB) PT Raised to $400 at Oppenheimer
January 26, 2018 6:46 AM ESTOppenheimer raised its price target on Biogen (NASDAQ: BIIB) to $400.00 (from $380.00) while maintaining a Outperform rating.
Analyst Jay Olson commented, "BIIB shares outperformed yesterday (+2.1% vs. NBI +0.7% and S&P 500 +0.1%) on strong 4Q17 financial results and confidence expressed by management regarding execution on key... More
Biogen (BIIB) PT Raised to $408 at Cowen
January 25, 2018 1:12 PM ESTCowen raised its price target on Biogen (NASDAQ: BIIB) to $408.00 (from $338.00) while maintaining an Outperform rating.
Analyst Eric Schmidt highlighted that the MS franchise is steady while Spinraza sales were strong as the drug's ex-U.S. launch has accelerated.
... MoreBiogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook
January 25, 2018 6:31 AM EST(Updated - January 25, 2018 6:33 AM EST)
Biogen (NASDAQ: BIIB) reported Q4 EPS of $5.26, $0.19 worse than the analyst estimate of $5.45. Revenue for the quarter came in at $3.31 billion versus the consensus estimate of $3.08 billion.
GUIDANCE:
Biogen sees FY2018 EPS of $24.20-$25.20... More
